DE2759543C2 - Verwendung von Spiro-hydantoin-Verbindungen bei der Bekämpfung von Diabetes - Google Patents

Verwendung von Spiro-hydantoin-Verbindungen bei der Bekämpfung von Diabetes

Info

Publication number
DE2759543C2
DE2759543C2 DE2759543A DE2759543A DE2759543C2 DE 2759543 C2 DE2759543 C2 DE 2759543C2 DE 2759543 A DE2759543 A DE 2759543A DE 2759543 A DE2759543 A DE 2759543A DE 2759543 C2 DE2759543 C2 DE 2759543C2
Authority
DE
Germany
Prior art keywords
spiro
udf54
udf53
compounds
chroman
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE2759543A
Other languages
German (de)
English (en)
Inventor
Reinhard New London Conn. Sarges
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US05/767,803 external-priority patent/US4117230A/en
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of DE2759543C2 publication Critical patent/DE2759543C2/de
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DE2759543A 1976-10-18 1977-10-14 Verwendung von Spiro-hydantoin-Verbindungen bei der Bekämpfung von Diabetes Expired DE2759543C2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73306276A 1976-10-18 1976-10-18
US05/767,803 US4117230A (en) 1976-10-18 1977-02-11 Hydantoin derivatives as therapeutic agents

Publications (1)

Publication Number Publication Date
DE2759543C2 true DE2759543C2 (de) 1987-04-09

Family

ID=27112515

Family Applications (4)

Application Number Title Priority Date Filing Date
DE2759543A Expired DE2759543C2 (de) 1976-10-18 1977-10-14 Verwendung von Spiro-hydantoin-Verbindungen bei der Bekämpfung von Diabetes
DE2759927A Expired DE2759927C2 (de) 1976-10-18 1977-10-14 Spiro-hydantoin-Verbindungen
DE2746244A Expired DE2746244C2 (de) 1976-10-18 1977-10-14 Derivate des Spiro [chroman-4,4'-imidazolidin] - 2',5'-dions
DE2759542A Expired DE2759542C2 (enrdf_load_stackoverflow) 1976-10-18 1977-10-14

Family Applications After (3)

Application Number Title Priority Date Filing Date
DE2759927A Expired DE2759927C2 (de) 1976-10-18 1977-10-14 Spiro-hydantoin-Verbindungen
DE2746244A Expired DE2746244C2 (de) 1976-10-18 1977-10-14 Derivate des Spiro [chroman-4,4'-imidazolidin] - 2',5'-dions
DE2759542A Expired DE2759542C2 (enrdf_load_stackoverflow) 1976-10-18 1977-10-14

Country Status (29)

Country Link
JP (3) JPS5353653A (enrdf_load_stackoverflow)
AR (1) AR220901A1 (enrdf_load_stackoverflow)
AT (1) AT356136B (enrdf_load_stackoverflow)
AU (1) AU504978B2 (enrdf_load_stackoverflow)
BG (1) BG28847A3 (enrdf_load_stackoverflow)
CA (1) CA1088945A (enrdf_load_stackoverflow)
CH (1) CH625511A5 (enrdf_load_stackoverflow)
DD (1) DD131931A5 (enrdf_load_stackoverflow)
DE (4) DE2759543C2 (enrdf_load_stackoverflow)
DK (1) DK150302C (enrdf_load_stackoverflow)
ES (1) ES463267A1 (enrdf_load_stackoverflow)
FI (1) FI62307C (enrdf_load_stackoverflow)
FR (1) FR2367754A1 (enrdf_load_stackoverflow)
GB (1) GB1566171A (enrdf_load_stackoverflow)
GR (1) GR70201B (enrdf_load_stackoverflow)
HK (1) HK53881A (enrdf_load_stackoverflow)
IE (1) IE45805B1 (enrdf_load_stackoverflow)
IL (1) IL53094A0 (enrdf_load_stackoverflow)
KE (1) KE3167A (enrdf_load_stackoverflow)
LU (1) LU78330A1 (enrdf_load_stackoverflow)
MX (1) MX4899E (enrdf_load_stackoverflow)
MY (1) MY8200157A (enrdf_load_stackoverflow)
NL (1) NL167434C (enrdf_load_stackoverflow)
NO (1) NO148453C (enrdf_load_stackoverflow)
NZ (1) NZ185358A (enrdf_load_stackoverflow)
PH (1) PH15639A (enrdf_load_stackoverflow)
PT (1) PT67164B (enrdf_load_stackoverflow)
SE (1) SE437024B (enrdf_load_stackoverflow)
YU (1) YU40821B (enrdf_load_stackoverflow)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4130714A (en) * 1977-05-23 1978-12-19 Pfizer Inc. Hydantoin therapeutic agents
US4127665A (en) * 1978-01-18 1978-11-28 Pfizer Inc. Thienohydantoin derivatives
US4147797A (en) * 1978-08-11 1979-04-03 Pfizer Inc. Spiro-furanohydantoin derivatives
US4200642A (en) * 1978-08-21 1980-04-29 Pfizer Inc. Spiro-oxazolidindiones
US4181728A (en) * 1978-11-16 1980-01-01 Pfizer Inc. Spiro-polycyclicimidazolidinedione derivatives
US4181729A (en) * 1979-03-21 1980-01-01 Pfizer Inc. Phenyl or phenoxy substituted spiro-imidazolidinedione derivatives
US4235911A (en) * 1979-06-13 1980-11-25 Pfizer Inc. Hydantoin derivatives
US4283409A (en) * 1979-10-29 1981-08-11 Pfizer Inc. Imidazolone derivatives
US4286098A (en) * 1980-03-28 1981-08-25 Pfizer Inc. Process for the preparation of chiral hydantoins
JPS5745185A (en) * 1980-07-21 1982-03-13 Eisai Co Ltd Hydantoin derivative and its preparation
ATE11781T1 (de) * 1981-05-13 1985-02-15 Imperial Chemical Industries Plc Pharmazeutische zubereitungen, die spirosuccinimidderivate enthalten.
JPS58213717A (ja) * 1982-01-20 1983-12-12 Eisai Co Ltd ヒダントイン誘導体を含有する治療用薬剤
JPS59500617A (ja) * 1982-04-15 1984-04-12 アルコン・ラボラトリ−ズ・インコ−ポレ−テッド ヒダントイン治療剤
ZA839023B (en) * 1982-12-06 1985-07-31 Pfizer Spiro-3-hetero-azolones for treatment of diabetic complications
US4474967A (en) * 1983-04-27 1984-10-02 Pfizer Inc. 8-Deutero and 8-tritio-substituted derivatives of D-4S-6-fluoro-spiro-[chroman-4,4'-imidazolidine]-2',5'-dione
WO1986002647A1 (en) * 1984-10-30 1986-05-09 Pfizer Inc. Spiro-heteroazolones for treatment of diabetes complications
JPS61200991A (ja) * 1985-03-04 1986-09-05 Sanwa Kagaku Kenkyusho:Kk スピロ―３―ヘテロアゾリジン化合物、その製法及びそれを有効成分とする糖尿病合併症の予防及び治療剤
US4575507A (en) * 1985-05-29 1986-03-11 Pfizer Inc. Spiro-imidazolidines as aldose reductase inhibitors and their pharmaceutical use
JPS6357588A (ja) * 1986-08-28 1988-03-12 Sanwa Kagaku Kenkyusho Co Ltd ヒダントイン誘導体、その塩並びに該化合物を有効成分とする糖尿病合併症の予防及び治療剤
WO1989001775A1 (en) * 1987-09-04 1989-03-09 Pfizer Inc. Azolidinedione derivatives
GB2355264A (en) 1999-09-30 2001-04-18 Merck & Co Inc Spirohydantoin derivatives useful as alpha 1a adrenoceptor antagonists
US7439383B2 (en) 2002-04-18 2008-10-21 University Of Virginia Patent Foundation Sodium channel blockers
FR2955107B1 (fr) 2010-01-08 2012-03-02 Servier Lab Nouveaux derives thiochromanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3821383A (en) * 1972-07-10 1974-06-28 Ayerst Mckenna & Harrison Compositions for and a method of treating diabetic complications

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB818724A (en) * 1956-10-18 1959-08-19 Ici Ltd Hydantoin derivatives
DE1135915B (de) * 1961-06-29 1962-09-06 Asta Werke Ag Chem Fab Verfahren zur Herstellung neuer, antikonvulsiv wirksamer Spirohydantoine
US3532744A (en) * 1967-07-28 1970-10-06 American Home Prod 1- and 2-amino substituted indane and tetralene carboxylic acids
DE2449030A1 (de) * 1974-10-11 1976-05-20 Schering Ag Neue pyridin-derivate
US4130714A (en) * 1977-05-23 1978-12-19 Pfizer Inc. Hydantoin therapeutic agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3821383A (en) * 1972-07-10 1974-06-28 Ayerst Mckenna & Harrison Compositions for and a method of treating diabetic complications

Also Published As

Publication number Publication date
DK150302B (da) 1987-02-02
FR2367754B1 (enrdf_load_stackoverflow) 1982-07-09
JPS5353653A (en) 1978-05-16
YU244277A (en) 1982-08-31
FI62307C (fi) 1982-12-10
NO773548L (no) 1978-04-19
DE2746244C2 (de) 1983-05-19
FR2367754A1 (fr) 1978-05-12
YU40821B (en) 1986-06-30
NZ185358A (en) 1979-06-08
GB1566171A (en) 1980-04-30
AR220901A1 (es) 1980-12-15
DK461377A (da) 1978-04-19
IE45805L (en) 1978-04-18
DE2759542C2 (enrdf_load_stackoverflow) 1988-07-07
ATA745977A (de) 1979-09-15
JPS5940388B2 (ja) 1984-09-29
CA1088945A (en) 1980-11-04
AU504978B2 (en) 1979-11-01
FI773060A7 (fi) 1978-04-19
DD131931A5 (de) 1978-08-09
NL7711358A (nl) 1978-04-20
KE3167A (en) 1981-11-06
AT356136B (de) 1980-04-10
DE2759927C2 (de) 1986-12-04
DK150302C (da) 1987-09-28
ES463267A1 (es) 1978-07-16
NL167434B (nl) 1981-07-16
IL53094A0 (en) 1977-12-30
DE2746244A1 (de) 1978-04-20
PT67164B (en) 1979-03-20
JPS5495570A (en) 1979-07-28
PT67164A (en) 1977-11-01
LU78330A1 (fr) 1979-06-01
BG28847A3 (bg) 1980-07-15
MX4899E (es) 1982-12-14
CH625511A5 (en) 1981-09-30
GR70201B (enrdf_load_stackoverflow) 1982-08-31
JPS5534132B2 (enrdf_load_stackoverflow) 1980-09-04
SE7711053L (sv) 1978-04-19
NO148453B (no) 1983-07-04
MY8200157A (en) 1982-12-31
FI62307B (fi) 1982-08-31
JPS607997B2 (ja) 1985-02-28
NO148453C (no) 1983-10-12
PH15639A (en) 1983-03-11
JPS5495575A (en) 1979-07-28
HK53881A (en) 1981-11-13
IE45805B1 (en) 1982-12-01
NL167434C (nl) 1981-12-16
AU2943177A (en) 1979-04-12
SE437024B (sv) 1985-02-04

Similar Documents

Publication Publication Date Title
DE2759543C2 (de) Verwendung von Spiro-hydantoin-Verbindungen bei der Bekämpfung von Diabetes
DE2858042C2 (de) Rechtsdrehendes Isomer eines asymmetrischen Spirohydantoins sowie der Basensalze hiervon und ihre Verwendung
DE69431568T2 (de) Inhibierung der migration und proliferation glatter muskeln mit hydroxycarbazolverbindungen
DE69617116T3 (de) Synergistische Zusammensetzung enthaltend einem Insulin-Sensibilisatormittel und einem HMG-CoA Reduktase Hemmer zur Behandlung von Arterosklerose
DE2901477C2 (de) Spirothienohydantoinderivate und diese enthaltende Arzneimittel
DE69711972T2 (de) Verwendung eines Aldose-Reduktase-Inhibitors zur Verminderung nicht-kardiologischer Gewebeschäden
DE3128606A1 (de) Hydantoinderivate, verfahren zu deren herstellung und arzneimittel, welche diese enthalten
DE3115383A1 (de) Antiallergisches mittel
DE3026402A1 (de) Die verwendung analgetischer und nicht-hormonaler, entzuendungshemmender mittel bei der behandlung von mikrovaskulaeren erkrankungen
DE69506197T2 (de) Verwendung eines Ascorbyl-tocopherylphosphats zur Herstellung eines Arzneimittels zur Behandlung der Pankreatitis
DE2946037A1 (de) Spiro-polycycloimidazolidindion-derivate und diese enthaltende arzneimittel
DE68915269T2 (de) Polyvalentes entzündungshemmendes mittel.
CH646057A5 (de) Mittel zur behandlung von glaucoma.
DE69013431T2 (de) Anthocyanidine zur Behandlung von Augenkrankheiten.
DE69630465T2 (de) Vorsorge-/heilmittel fur die komplikationen von diabetes
DE2926463C2 (enrdf_load_stackoverflow)
DD264213A5 (de) Verfahren zur herstellung eines spiroimidazolidins
DE3874900T2 (de) Wirkstoff mit die nierenfunktion verbesserndem und diuretischem effekt und verwendung eines darin enthaltenen benzothiazepin-derivates.
DE69907387T2 (de) Verwendung von Hydantoin-Derivaten zur Herstellung eines Medikaments zur Behandlung von refraktärer Vasculitis.
DE69023045T2 (de) Carboxamidderivate.
DE1280844B (de) N-(p-Chlorbenzolsulfonyl)-N'-n-propyl-harnstoff und Verfahren zu dessen Herstellung
DE4202184A1 (de) Substituierte salicylaldehyde zur behandlung von krankheiten
DE69105069T2 (de) Verwendung einer Verbindung zur Herstellung eines Arzneimittels zur Senkung des Harnsäuregehalts des Blutes.
DE69528068T2 (de) Conagenine zur prävention und behandlung von diarrhöe
DE3904795C2 (de) Pharmazeutisches Präparat und dessen Verwendung

Legal Events

Date Code Title Description
OI Miscellaneous see part 1
OI Miscellaneous see part 1
Q161 Has additional application no.

Ref document number: 2858042

Country of ref document: DE

8110 Request for examination paragraph 44
AC Divided out of

Ref country code: DE

Ref document number: 2746244

Format of ref document f/p: P

D2 Grant after examination
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee